Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.

HUTCHMED vs Xencor: A Decade of Cost Dynamics

__timestampHUTCHMED (China) LimitedXencor, Inc.
Wednesday, January 1, 20147204900018516000
Thursday, January 1, 201511077700034140000
Friday, January 1, 201615632800051872000
Sunday, January 1, 201717582000071772000
Monday, January 1, 201814394400097501000
Tuesday, January 1, 2019160152000118590000
Wednesday, January 1, 2020188519000169802000
Friday, January 1, 20212582340007491000
Saturday, January 1, 20223111030008799000
Sunday, January 1, 2023384447000253598000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. HUTCHMED (China) Limited and Xencor, Inc. offer a fascinating comparison. Over the past decade, HUTCHMED's cost of revenue has surged by over 430%, from approximately $72 million in 2014 to nearly $384 million in 2023. This growth reflects their expanding operations and market reach. In contrast, Xencor, Inc. experienced a more volatile trajectory, with costs peaking at around $254 million in 2023, a significant leap from just $7 million in 2021. This fluctuation highlights the dynamic nature of biotech investments and the challenges of scaling operations. As these companies navigate the complexities of their industries, their cost of revenue trends provide valuable insights into their strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025